Evidence map›Paper›PMID 29547630›Full record

ArticlePloS one2018

Biophysical characterization of hit compounds for mechanism-based enzyme activation.

Xiangying Guan, Alok Upadhyay, Sudipto Munshi, Raj Chakrabarti

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xiangying GuanDivision of Fundamental Research, Chakrabarti Advanced Technology, Mount Laurel, New Jersey, United States of America.
Alok UpadhyayDivision of Fundamental Research, Chakrabarti Advanced Technology, Mount Laurel, New Jersey, United States of America.
Sudipto MunshiDivision of Fundamental Research, Chakrabarti Advanced Technology, Mount Laurel, New Jersey, United States of America.
Raj ChakrabartiDivision of Fundamental Research, Chakrabarti Advanced Technology, Mount Laurel, New Jersey, United States of America.ORCID 0000-0002-8685-452X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Across all families of enzymes, only a dozen or so distinct classes of non-natural small molecule activators have been characterized, with only four known modes of activation among them. All of these modes of activation rely on naturally evolved binding sites that trigger global conformational changes. Among the enzymes that are of greatest interest for small molecule activation are the seven sirtuin enzymes, nicotinamide adenine dinucleotide (NAD+)-dependent protein deacylases that play a central role in the regulation of healthspan and lifespan in organisms ranging from yeast to mammals. However, there is currently no understanding of how to design sirtuin-activating compounds beyond allosteric activators of SIRT1-catalyzed reactions that are limited to particular substrates. Here, we introduce a general mode of sirtuin activation that is distinct from the known modes of enzyme activation. Based on the conserved mechanism of sirtuin-catalyzed deacylation reactions, we establish biophysical properties of small molecule modulators that can in principle result in enzyme activation for diverse sirtuins and substrates. Building upon this framework, we propose strategies for the identification, characterization and evolution of hits for mechanism-based enzyme activating compounds.

Indexed as

Models, ChemicalEnzyme ActivationEnzyme ActivatorsHumansNADSirtuin 1Enzyme ActivatorsNADSIRT1 protein, humanSirtuin 1

Identifiers

PMID29547630
PMCPMC5856274
OpenAlexW2792894684

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.